- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03258320
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis
A Phase I Study of Neoadjuvant Chemotherapy Involving Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Followed by Surgery for Patients With High Risk Localized Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prostate cancer is the development of neoplasia in the prostate, a major gland in the male reproductive system. While most prostate cancers grow slowly, some can develop relatively quickly and aggressively. In a later stage of the disease, cancer cells may disseminate from the prostate to other organs of the body, particularly the bone, lung, brain and lymph node. Prostate cancer initially cause no symptoms, but in an advanced stage it can cause difficulty in urinating, blood in the urine, or pain in the pelvis. A non-malignant or precursor form of prostate cancer known as benign prostatic hyperplasia may produce similar symptoms, although it is essentially not invasive.
Many prostate cancer patients can be safely followed with active surveillance or watchful actions. However, the major forms of clinical treatments include a combination of surgery, radiation, hormone therapy or chemotherapy. If it only occurs inside the prostate, the disease is generally curable. However, when cancer cells have spread to the bones, cytotoxic or harsh therapies are necessary. Outcomes depend on a person's age and other health conditions as well as how aggressive and extensive the cancer is. Most people with prostate cancer do not end up dying from the disease, and the 5-year survival rate in the United States is approximately 99%. To date, it is the 2nd most common type of malignancy and the 5th leading cause of cancer-related death in men. In 2012 it affected 1.1 million men and claimed 307,000 deaths. Prostate cancer occur more frequently in the western countries or developed world, but incidence rates have been continuously arising in the developing countries. Clinical detection increased significantly in the 1980s and 1990s in the global range due to development of the gold standard--PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over the age of 60.
Most hormone-naive prostate cancers become resistant to treatments after 1-3 years and resume growth despite hormone therapy, a condition termed as "hormone-refractory prostate cancer" (HRPC) or "castration-resistant prostate cancer (CRPC)". The most prevalent chemotherapeutic agent docetaxel (Taxotere) has been used as a standardized modality for CRPC and provides a median survival benefit of 2-3 months. A second-line chemotherapy involves cabazitaxel. Although combination of bevacizumab, docetaxel, thalidomide and prednisone appears effective in the treatment of CRPC, these agents are usually used after the occurrence of CRPC, not before. Thus, whether or not these patients should receive chemotherapy prior to development of CRPC, and whether this approach can prevent the aggressive progression of the disease to a treatment refractory status, remain largely open but intriguing questions.
In this study, investigators performed a Phase I, single agent exploration, multicenter clinical trial to establish the treatment efficacy of several chemotherapeutic agents in patients with high risk localized prostate cancer who have developed the primary cancer in prostate. Up to 5 cohorts have been enrolled to determine the effectiveness and safety of single therapeutic strategy. Besides the five-year disease-free survival, overall survival and five-year metastasis-free survival post treatment, investigators also take into account the anticancer agent-induced tumor stroma damage extent, which may provide further evidence to support the treatment efficacy and assess the potential influence of a damaged tumor microenvironment on disease progression or regression in clinical settings.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Weijun Ma, Ph.D
- Phone Number: 86-21-54923268
- Email: wjma@sibs.ac.cn
Study Contact Backup
- Name: Yu Sun, Ph.D
- Phone Number: 86-21-54923302
- Email: sunyu@sibs.ac.cn
Study Locations
-
-
-
Shanghai, China, 200032
- Recruiting
- Zhongshan hospital
-
Contact:
- Qilai Long, Ph.D
- Phone Number: 86-15821758764
- Email: long.qilai@zs-hospital.sh.cn
-
-
Shandong
-
Qingdao, Shandong, China, 266035
- Recruiting
- Qilu Hospital of Shandong University
-
Contact:
- Jiannan Chen, Ph.D
- Phone Number: 86-0532-96599654
- Email: submarinesuny@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 40 ≤ age ≤ 75 years with histologically proven PCa
- no severe major organ dysfunction
- WHO performance status of 0 or 1
- no prior cancer chemotherapy
- A Clinical Stage ≥ T2c (T2c, N0, M0) of prostate cancer but without diagnosed distant metastasis (according to the 2016 American Joint Committee on Cancer (AJCC) definition of TNM staging system, Staging Manual, Eighth Edition) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan.
Exclusion Criteria:
- age ≥ 76
- severe major organ dysfunction
- WHO performance status of >1
- prior cancer chemotherapy
- Stage IV.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CDMS, Surgery
Preoperative chemotherapy using Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) as a single agent performed 45 days before surgery:Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery. Procedure: radical prostatectomy surgery. |
As preoperative neoadjuvant chemotherapy, drugss including Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) will be administered as a single agent performed 45 days before surgery:Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration.
IV or oral administration once every 7 days, totally 4 cycles.
There is a 17-day interval between the last dose and surgery.
Other Names:
|
No Intervention: Control
No neoadjuvant chemotherapy using CDMS will be done for patients who are diagnosed with localized prostate cancer but subject to direct surgery to radically remove the primary tumor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
5 years disease-free survival
Time Frame: 5 years
|
There is no disease-associated progression during the 5 years post treatment (chemotherapy plus surgery).
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
5 years overall survival and metastasis-free survival
Time Frame: 5 years
|
The overall survival status and distant metastasis-free survival status during the 5 years post treatment (chemotherapy plus surgery).
|
5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yu Sun, Ph.D, Shanghai Jiao Tong University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Docetaxel
- Mitoxantrone
- Satraplatin
Other Study ID Numbers
- PCA-81472709
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer Patients
-
Abramson Cancer Center of the University of PennsylvaniaCompletedProstate Cancer PatientsUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaRecruiting
-
Azienda Ospedaliero-Universitaria CareggiCompletedMetastatic Prostate Cancer | Elderly PatientsItaly
-
Corporacion Parc TauliUnknownPatients With Suspected Prostate CancerSpain
-
University of Guelph-HumberUniversity Health Network, Toronto; McGill University Health Centre/Research... and other collaboratorsCompletedProstate Cancer Patients Undergoing Radical ProstatectomyCanada
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedMetastatic Castration Resistant Prostate Cancer PatientsFrance
-
CS Diagnostics GmbHAix ScientificsTerminatedProstate Cancer Patients Treated by RadiotherapyGermany
-
Sir Mortimer B. Davis - Jewish General HospitalRecruitingCastration-resistant Prostate Cancer Patients With OligometastasesCanada
Clinical Trials on Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin
-
Erasmus Medical CenterRecruitingMetastatic Castration-resistant Prostate CancerNetherlands
-
Xencor, Inc.RecruitingMetastatic Castration-Resistant Prostate CancerUnited States
-
Azienda Ospedaliero-Universitaria CareggiCompletedMetastatic Prostate Cancer | Elderly PatientsItaly
-
University of Michigan Rogel Cancer CenterCompletedProstate CancerUnited States
-
Optimal Health ResearchCompletedBreast Cancer | Lung Cancer | Prostate CancerUnited States
-
UNICANCERInstitut Bergonié; National Cancer Institute, France; Institut du Cancer de Montpellier...CompletedChemotherapy | Castration-resistant Prostate Cancer | Prostate Carcinoma | Circulating Tumor CellsFrance
-
Arbeitsgemeinschaft fur Internistische OnkologieCompletedBreast CancerGermany
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)CompletedProstate CancerUnited States